{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:13:50Z","timestamp":1788434030246,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biopha.2023.115352","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:54:07Z","timestamp":1692903247000},"page":"115352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints"],"prefix":"10.1016","volume":"166","author":[{"given":"Gabriel O.","family":"Rodr\u00edguez-V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana O.","family":"Diaz-Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-6802","authenticated-orcid":false,"given":"Nataliya","family":"Chorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris K.","family":"Salgado-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter I. Silva","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor M.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2023.115352_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.115352_bib2","first-page":"2022","article-title":"The global burden of leukemia and its attributable factors in 204 countries and territories: findings from the global burden of disease 2019 study and projections to 2030","author":"Du","year":"2022","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib3","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca. Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0641-1","article-title":"Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia","volume":"11","author":"Ghelli Luserna Di Ror\u00e0","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115352_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jtct.2022.08.024","article-title":"Long-term results of allogeneic stem cell transplantation in adult Ph- negative high-risk acute lymphoblastic leukemia","volume":"28","author":"Beelen","year":"2022","journal-title":"Transplant. Cell. Ther."},{"issue":"15","key":"10.1016\/j.biopha.2023.115352_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13153886","article-title":"Why do children with acute lymphoblastic leukemia fare better than adults?","volume":"13","author":"Neaga","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2023.115352_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.biopha.2023.115352_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms221910689","article-title":"Wee1 kinase: a potential target to overcome tumor resistance to therapy","volume":"22","author":"Esposito","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115352_bib9","first-page":"1","article-title":"No place for Wee1 in Astra \u2019 s synthetic lethality work","author":"Plieth","year":"2022","journal-title":"Eval. Vantage"},{"issue":"October","key":"10.1016\/j.biopha.2023.115352_bib10","article-title":"Recent advances of WEE1 inhibitors and statins in cancers with p53 Mutations","volume":"8","author":"Meng","year":"2021","journal-title":"Front. Med."},{"issue":"December 2019","key":"10.1016\/j.biopha.2023.115352_bib11","article-title":"WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry","volume":"819\u2013820","author":"Elb\u00e6k","year":"2020","journal-title":"Mutat. Res. - Fundam. Mol. Mech. Mutagen."},{"issue":"23","key":"10.1016\/j.biopha.2023.115352_bib12","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1158\/0008-5472.CAN-17-2066","article-title":"Recent advances of cell-cycle inhibitor therapies for pediatric cancer","volume":"77","author":"Mills","year":"2017","journal-title":"Cancer Res"},{"issue":"30","key":"10.1016\/j.biopha.2023.115352_bib13","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors","volume":"33","author":"Do","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115352_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057523","article-title":"Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas","volume":"8","author":"Kreahling","year":"2013","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.biopha.2023.115352_bib15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1276.1276","article-title":"The wee1 inhibitor, MK-1775, sensitizes leukemic cells to different antineoplastic drugs interfering with DNA damage response pathway","volume":"126","author":"Ghelli Luserna Di Rora","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2023.115352_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2019.08.163","article-title":"Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines","volume":"519","author":"Barbosa","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.biopha.2023.115352_bib17","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood-2011-07-367557","article-title":"RNAi screening of the kinome with cytarabine in leukemias","volume":"119","author":"Tibes","year":"2012","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.biopha.2023.115352_bib18","doi-asserted-by":"crossref","first-page":"28001","DOI":"10.18632\/oncotarget.4830","article-title":"AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair","volume":"6","author":"Ford","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2023.115352_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"Synergyfinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom., Proteom. Bioinforma."},{"key":"10.1016\/j.biopha.2023.115352_bib20","doi-asserted-by":"crossref","unstructured":"Jameel S., Jahan P., Ramasamy S. A Path to Protein Quantitation: PBMCs to Western Blot. 2023;2(1):12\u201327.","DOI":"10.21467\/ijm.2.1.6584"},{"issue":"5","key":"10.1016\/j.biopha.2023.115352_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.tiv.2004.03.012","article-title":"Comparison of alamar blue and MTT assays for high through-put screening","volume":"18","author":"Hamid","year":"2004","journal-title":"Toxicol. Vitr."},{"issue":"8","key":"10.1016\/j.biopha.2023.115352_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3109\/15376516.2010.508080","article-title":"Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (-\/- gossypol)","volume":"20","author":"Uzunoglu","year":"2010","journal-title":"Toxicol. Mech. Methods"},{"issue":"18","key":"10.1016\/j.biopha.2023.115352_bib23","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.biopha.2023.115352_bib24","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.21873\/anticanres.13472","article-title":"To combine or not combine: drug interactions and tools for their analysis. Reflections from the EORTC-PAMM course on preclinical and early-phase clinical pharmacology","volume":"39","author":"Hassouni","year":"2019","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-10878-x","article-title":"Thiamine antagonists trigger p53-dependent apoptosis in differentiated SH-SY5Y cells","volume":"7","author":"Chornyy","year":"2017","journal-title":"Sci. Rep."},{"issue":"April","key":"10.1016\/j.biopha.2023.115352_bib26","first-page":"1","article-title":"Severity-dependent profile of the metabolome in hypospadias","volume":"8","author":"Pi\u00f1eyro-Ruiz","year":"2020","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.biopha.2023.115352_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11020278","article-title":"Effects of ferroptosis on the metabolome in cardiac cells: the role of glutaminolysis","volume":"11","author":"Rodr\u00edguez-Graciani","year":"2022","journal-title":"Antioxidants"},{"issue":"W1","key":"10.1016\/j.biopha.2023.115352_bib28","doi-asserted-by":"crossref","first-page":"W388","DOI":"10.1093\/nar\/gkab382","article-title":"MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights","volume":"49","author":"Pang","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2023.115352_bib29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"5","key":"10.1016\/j.biopha.2023.115352_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput. Biol."},{"issue":"March","key":"10.1016\/j.biopha.2023.115352_bib31","first-page":"1","article-title":"WEE1 inhibition in combination with targeted agents and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma","volume":"11","author":"Hartman","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115352_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11060402","article-title":"Asparagine: a metabolite to be targeted in cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Metabolites"},{"issue":"7692","key":"10.1016\/j.biopha.2023.115352_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature25465","article-title":"Asparagine bioavailability governs metastasis in a model of breast cancer","volume":"554","author":"Knott","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-022-00878-z","article-title":"Cancer-derived extracellular succinate: a driver of cancer metastasis","volume":"29","author":"Kuo","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2023.115352_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2012.00085","article-title":"The emerging role of fumarate as an oncometabolite","volume":"2","author":"Yang","year":"2012","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115352_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv426","article-title":"Role of Increased n-acetylaspartate levels in cancer","volume":"108","author":"Zand","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.biopha.2023.115352_bib37","first-page":"1","article-title":"Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy","volume":"6","author":"Asaka","year":"2019","journal-title":"Mol. Cell. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2023.115352_bib38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.2019001034","article-title":"Amino acid metabolism in hematologic malignancies and the era of targeted therapy","volume":"134","author":"Tabe","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31248-w","article-title":"Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance","volume":"13","author":"Xia","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10508-2","article-title":"Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells","volume":"10","author":"Kampen","year":"2019","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2023.115352_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1832-6","article-title":"Targeting HIBCH to reprogram valine metabolism for the treatment of colorectal cancer","volume":"10","author":"Shan","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115352_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.15430\/JCP.2021.26.4.237","article-title":"Role of branched-chain amino acid metabolism in tumor development and progression","volume":"26","author":"Jung","year":"2021","journal-title":"J. Cancer Prev."},{"issue":"10","key":"10.1016\/j.biopha.2023.115352_bib43","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/sj.leu.2401139","article-title":"Apoptosis of leukemia cells induced by valine-deficient medium [1]","volume":"12","author":"Ohtawa","year":"1998","journal-title":"Leukemia"},{"issue":"7893","key":"10.1016\/j.biopha.2023.115352_bib44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-021-04244-1","article-title":"Valine tRNA levels and availability regulate complex I assembly in leukaemia","volume":"601","author":"Thandapani","year":"2022","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.biopha.2023.115352_bib45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41586-022-04499-2","article-title":"Tryptophan depletion results in tryptophan-to-phenylalanine substitutants","volume":"603","author":"Pataskar","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115352_bib46","doi-asserted-by":"crossref","unstructured":"Wang H., Chen S., Kang W., et al. High dose isoleucine stabilizes nuclear PTEN to suppress the proliferation of lung cancer. Discov. Oncol. 2023;","DOI":"10.1007\/s12672-023-00634-1"},{"issue":"12","key":"10.1016\/j.biopha.2023.115352_bib47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12032-021-01577-9","article-title":"The apoptotic efficacy of succinic acid on renal cancer cell lines","volume":"38","author":"Kasarci","year":"2021","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115352_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.arcmed.2020.10.022","article-title":"In vitro inhibitory effect of succinic acid on T-cell acute lymphoblastic leukemia cell lines","volume":"52","author":"Ertugrul","year":"2021","journal-title":"Arch. Med. Res."},{"issue":"JULY","key":"10.1016\/j.biopha.2023.115352_bib49","first-page":"1","article-title":"Wee1 inhibitor AZD1775 effectively inhibits the malignant phenotypes of esophageal squamous cell carcinoma in Vitro and in Vivo","volume":"10","author":"Bi","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"04","key":"10.1016\/j.biopha.2023.115352_bib50","first-page":"20","article-title":"CD34-negative B-lymphoblastic leukemia\/lymphoma presenting as cutenous lesions at infancy: a case report","volume":"10","author":"Lotodo","year":"2022","journal-title":"J. Biosci. Med."},{"issue":"16096","key":"10.1016\/j.biopha.2023.115352_bib51","first-page":"53","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.biopha.2023.115352_bib52","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3324\/haematol.2019.231126","article-title":"WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia","volume":"106","author":"Hu","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.biopha.2023.115352_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.leukres.2017.11.004","article-title":"Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine","volume":"64","author":"Garcia","year":"2018","journal-title":"Leuk. Res."},{"issue":"23","key":"10.1016\/j.biopha.2023.115352_bib54","doi-asserted-by":"crossref","first-page":"20196","DOI":"10.1021\/acsomega.3c01558","article-title":"Synthetic and medicinal chemistry approaches toward WEE1 kinase inhibitors and its degraders","volume":"8","author":"Alli","year":"2023","journal-title":"ACS Omega"},{"issue":"14","key":"10.1016\/j.biopha.2023.115352_bib55","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors A C","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.115352_bib56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1083\/jcb.201101047","article-title":"Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease","volume":"194","author":"Dom\u00ednguez-Kelly","year":"2011","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115352_bib57","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3324\/haematol.2019.231126","article-title":"WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia","volume":"106","author":"Hu","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2023.115352_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101674","article-title":"Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement","volume":"37","author":"Nolfi-Donegan","year":"2020","journal-title":"Redox Biol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115352_bib59","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1042\/BST20160094","article-title":"The Warburg effect: 80 years on","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.biopha.2023.115352_bib60","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1113\/JP278810","article-title":"Revisiting the Warburg effect: historical dogma versus current understanding","volume":"599","author":"Vaupel","year":"2021","journal-title":"J. Physiol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115352_bib61","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7150\/jca.14274","article-title":"Warburg effect - a consequence or the cause of carcinogenesis?","volume":"7","author":"Devic","year":"2016","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2023.115352_bib62","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115352_bib63","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/CM9.0000000000002642","article-title":"Ferroptosis in acute leukemia","volume":"136","author":"Lyu","year":"2023","journal-title":"Chin. Med. J."},{"issue":"8","key":"10.1016\/j.biopha.2023.115352_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081128","article-title":"Molecular mechanisms of ferroptosis and updates of ferroptosis studies in cancers and leukemia","volume":"12","author":"Akiyama","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00726-017-2490-6","article-title":"Roles of dietary glycine, proline, and hydroxyproline in collagen synthesis and animal growth","volume":"50","author":"Li","year":"2018","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2058-1","article-title":"The role of collagen in cancer: from bench to bedside","volume":"17","author":"Xu","year":"2019","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-14","article-title":"\u0392-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro","volume":"13","author":"Vaughan","year":"2014","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.51354\/mjen.848282","article-title":"Anticarcinogenic properties of malic acid on glioblastoma cell line through necrotic cell death mechanism","volume":"9","author":"ARSLAN","year":"2021","journal-title":"MANAS J. Eng."},{"key":"10.1016\/j.biopha.2023.115352_bib69","first-page":"2021","article-title":"Metabolomic profiling identified serum metabolite biomarkers and related metabolic pathways of colorectal cancer","author":"Zhang","year":"2021","journal-title":"Dis. Markers"},{"key":"10.1016\/j.biopha.2023.115352_bib70","doi-asserted-by":"crossref","unstructured":"Jin J., Byun J., Choi Y. Targeting glutamine metabolism as a therapeutic strategy for cancer. 2023;(January):","DOI":"10.1038\/s12276-023-00971-9"},{"key":"10.1016\/j.biopha.2023.115352_bib71","doi-asserted-by":"crossref","unstructured":"Claiborne M.D., Leone R. Differential glutamine metabolism in the tumor microenvironment \u2013 studies in diversity and heterogeneity: A mini-review. 2022;(September):1\u20138.","DOI":"10.3389\/fonc.2022.1011191"},{"issue":"8","key":"10.1016\/j.biopha.2023.115352_bib72","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.31557\/APJCP.2020.21.8.2463","article-title":"Clinical significance of plasma levels of gluconeogenic amino acids in esophageal cancer patients","volume":"21","author":"Taherizadeh","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"17","key":"10.1016\/j.biopha.2023.115352_bib73","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.7150\/jca.21125","article-title":"The glycolytic switch in tumors: how many players are involved?","volume":"8","author":"Yu","year":"2017","journal-title":"J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2023.115352_bib74","doi-asserted-by":"crossref","first-page":"13349","DOI":"10.18632\/aging.202962","article-title":"Emerging roles of nucleotide metabolism in cancer development: progress and prospect","volume":"13","author":"Ma","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"January","key":"10.1016\/j.biopha.2023.115352_bib75","article-title":"Metabolism of amino acids in cancer","volume":"8","author":"Wei","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13668-3","article-title":"Mitochondrial TCA cycle metabolites control physiology and disease","volume":"11","author":"Mart\u00ednez-Reyes","year":"2020","journal-title":"Nat. Commun."},{"issue":"6365","key":"10.1016\/j.biopha.2023.115352_bib77","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1126\/science.aam9305","article-title":"Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass","volume":"358","author":"Spinelli","year":"2017","journal-title":"Sci. (80-. )"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-81725-3","article-title":"Evaluation of the correlation between porphyrin accumulation in cancer cells and functional positions for application as a drug carrier","volume":"11","author":"Nishida","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115352_bib79","unstructured":"Yeo E., Kang I. Functions, and Therapeutic Potential in Cancer. 2022;"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbcan.2019.05.006","article-title":"Gluconeogenesis in cancer cells \u2013 repurposing of a starvation-induced metabolic pathway?","volume":"1872","author":"Grasmann","year":"2019","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115352_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01358-5","article-title":"Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications","volume":"15","author":"Zhong","year":"2022","journal-title":"J. Hematol. Oncol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:29:55Z","timestamp":1782372595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223011435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":81,"alternative-id":["S0753332223011435"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115352","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115352"}}